Projects per year
Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.
- 12 Similar Profiles
Inflammatory Bowel Diseases
Medicine & Life Sciences
Crohn Disease
Medicine & Life Sciences
Colitis
Medicine & Life Sciences
Ulcerative Colitis
Medicine & Life Sciences
Inflammation
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Macrophages
Medicine & Life Sciences
Dextran Sulfate
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 1995 2019
Host Innate Immune-Microbial Interactions in Intestinal Inflammation
Sartor, R. B., Herfarth, H. H., Ting, J. P., Azcarate-Peril, M. A. & Sheikh, S. Z.
NIH National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDKD)
9/19/13 → 6/30/18
Project: Research project
Microbial Interactions
Research Personnel
Inflammation
Zebrafish
Breeding
C87075 A Non-Interventional Long Term Post Marketing Registry of Patients Tre
Isaacs, K. L. & Herfarth, H. H.
5/18/09 → 5/17/19
Project: Research project
Marketing
Registries
Crohn Disease
Physicians
Aplastic Anemia
Research Ititiatives: Clinical Alliance Administrative - CCFA REF# 35710
Crohns and Colitis Foundation of America (CCFA)
3/1/15 → 6/30/16
Project: Research project
Multi-omic model for Prediction of Postoperative Crohn's Disease Recurrence
Herfarth, H. H. & Sartor, R. B.
11/1/14 → 10/31/15
Project: Research project
Crohn Disease
Recurrence
Ileal Diseases
Demography
Surgical Pathology
A Double-Blind, Placebo-Controlled, Parallel-Group, Muticenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn's Disease
10/31/14 → 12/31/17
Project: Research project
Research Output 1994 2018
Clinical disease activity in the CALM study
Herfarth, H., Long, M. D. & Isaacs, K. L. Apr 14 2018 In : The Lancet. 391, 10129, p. 1481-1482 2 p.Research output: Contribution to journal › Letter
IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis?
Proksell, S. S., Greer, J. B., Theisen, B. K., Davis, P. L., Rosh, J. R., Keljo, D. J., Goyal, A., Shah, S. A., Brand, M. H., Herfarth, H. H., Cross, R. K., Siegel, C. A., Koltun, W. A., Isaacs, K. L. & Regueiro, M. D. Mar 19 2018 In : Inflammatory bowel diseases. 24, 4, p. 698-713 16 p.Research output: Contribution to journal › Article
Colitis
Therapeutics
Is There a Role for Thiopurines in IBD?
Cross, R. K. & Herfarth, H. Jun 27 2018 (Accepted/In press) In : American Journal of Gastroenterology. p. 1-4 4 p.Research output: Contribution to journal › Article
8
Citations
Molecular classification of Crohn's disease reveals two clinically relevant subtypes
Weiser, M., Simon, J. M., Kochar, B., Tovar, A., Israel, J. W., Robinson, A., Gipson, G. R., Schaner, M. S., Herfarth, H. H., Sartor, R. B., McGovern, D. P. B., Rahbar, R., Sadiq, T. S., Koruda, M. J., Furey, T. S. & Sheikh, S. Z. Jan 1 2018 In : Gut. 67, 1, p. 36-42 7 p.Research output: Contribution to journal › Article
Crohn Disease
Ileum
Colon
Phenotype
Gene Expression
Teduglutide for the treatment of short bowel syndrome – a safety evaluation
Kochar, B. & Herfarth, H. H. Jun 9 2018 (Accepted/In press) In : Expert Opinion on Drug Safety. p. 1-7 7 p.Research output: Contribution to journal › Article
Short Bowel Syndrome
Safety
Glucagon-Like Peptide 2
Therapeutics
Controlled Clinical Trials